Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

5,18

 

EUR

 

+2,37 %

NXTMH

First North Finland

Medical Equipment & Services

Health Care

5.241 investorer følger denne virksomhed
+2,37%
-1,15%
-13,67%
+66,56%
+79,86%
+76,19%
+103,94%
-1,89%
+122,66%
-99,14%
www.nexstim.com/investors/company-profile

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

P/E (adj.) (24e)
-388,94
EV/EBIT (adj.) (24e)
12.376,85
P/B (24e)
13,82
Udbytteafkast, % (24e)
-
Kursmål
4.00 EUR
Anbefaling
Sælg
Opdateret
20.10.2024
First North Finland
NXTMH
Daglig lav / høj pris
5,06 / 5,3 EUR
Markedsværdi
35,05 mio. EUR
Aktieomsætning
4,14 t EUR
Volumen
811
Business risk
Valuation risk
Current
Previous

Seneste analyser

Nexstim: Taking a breather after handsome returns
21.10.2024
Nexstim Q2'24: Potential attracts again
19.08.2024
Nexstim: Disagreements over license agreement
13.06.2024

Extensive report

Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the report

Analytiker

Antti Siltanen
Antti Siltanen
Analytiker

Seneste videoer

Nexstim: More sales with licenses
09.10.2023
Nexstim: Stimulating Earnings Turnaround
16.08.2022

Finanskalender

Årsrapport
27.02.2025

Resultatopgørelse

20202021202220232024e2025e2026e2027e
Omsætning4,16,49,57,29,111,914,115,2
vækst-%22,9 %55,5 %48,9 %-23,9 %25,9 %29,9 %19,1 %7,4 %
EBITDA-3,0-1,01,3-0,50,81,62,42,9
EBIT (adj.)-3,3-1,50,8-1,20,01,01,92,3
EBIT-3,3-1,50,8-1,20,01,01,92,3
Overskud før skat-4,1-0,71,3-1,3-0,10,91,72,2
Netto indkomst-4,1-0,81,3-1,3-0,10,91,72,2
EPS (adj.)-0,01-0,110,18-0,18-0,010,120,240,30
vækst-%-201,5 %98,1 %26,3 %
Udbytte0,000,000,000,000,000,000,060,15
Udbytte ratio25,0 %50,0 %

Lønsomhed og afkast på kapital

20202021202220232024e2025e2026e2027e
EBITDA-%-72,1 %-15,8 %13,8 %-7,3 %8,9 %13,7 %17,0 %18,9 %
EBIT-% (adj.)-81,0 %-22,7 %8,8 %-16,9 %0,0 %8,2 %13,1 %15,1 %
EBIT-%-81,0 %-22,7 %8,8 %-16,9 %0,0 %8,2 %13,1 %15,1 %
ROE373,1 %-96,0 %36,0 %-38,5 %-3,5 %27,6 %38,8 %35,2 %
ROI-73,1 %-27,2 %11,4 %-16,6 %0,0 %14,5 %26,6 %27,8 %

Værdiansættelse

20202021202220232024e2025e2026e2027e
Aktiekurs (EUR)0,104,784,002,695,185,185,185,18
Aktier439,67,37,37,37,37,37,37,3
Markedsværdi43,134,829,119,637,737,737,737,7
Enterprise value44,733,528,122,539,037,535,334,4
EV/S10,95,23,03,14,33,22,52,3
EV/EBITDA--21,4-48,123,114,712,0
EV/EBIT (adj.)--33,6-12.375,638,519,015,1
EV/EBIT--33,6-12.375,638,519,015,1
P/E (adj.)--22,2--43,121,817,2
P/E--22,2--43,121,817,2
P/B-10,97,16,913,810,57,15,3
P/S10,55,43,12,74,13,22,72,5
Udbytteprocent1,2 %2,9 %
Equity ratio-23,5 %31,9 %39,8 %28,6 %25,7 %31,2 %40,5 %48,7 %
Gearing ratio-108,1 %-40,6 %-23,4 %105,6 %50,1 %-5,2 %-45,0 %-45,9 %

Kvartalsdata

Q1/23Q2/23Q3/23Q4/232023Q1/24eQ2/24eQ3/24eQ4/24e
Omsætning2,54,77,23,25,9
EBITDA-1,10,6-0,5-0,51,3
EBIT-1,40,2-1,2-0,90,9
Overskud før skat-1,40,1-1,3-0,90,8
Netto indkomst-1,40,1-1,3-0,90,8
Login in to make your own estimates and see other investors estimates.
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Business news update from Nexstim
Analytikerkommentar af
Antti Siltanen

Business news update from Nexstim

Nexstim issued a press release on business highlights for January-September. The company said it has invested in profitable growth, development of its NBS 6 diagnostics product and expansion of its network of clinics.

Nexstim
Analyse af
Antti Siltanen

Nexstim: Taking a breather after handsome returns

On Friday, Nexstim announced that it had obtained a license in India, which means an authorization to sell the NBS5 system in a new market. We raised our medium- and long-term forecasts based on the new market opening, although the visibility of the Indian market is very limited.

Nexstim
Analyse af
Antti Siltanen

Nexstim Q2'24: Potential attracts again

Nexstim's H1 report was broadly in line with expectations and the company reaffirmed its outlook for the remainder of the year for comparable revenue growth and improved EBIT. Our forecast revisions are minor as the company's outlook remains largely unchanged.

Nexstim